Dosing & Uses
Dosage Forms & Strengths
nasal spray
- 0.05% (20mL)
Nasal Decongestant
1-2 sprays per nostril q6hr PRN
Dosage Forms & Strengths
nasal spray
- 0.05% (20mL)
Nasal Decongestant
< 12 years
- Not recommended
>12 years
- 1-2 sprays per nostril q6hr PRN
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (1)
- iobenguane I 131
naphazoline will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.
Monitor Closely (3)
- nicotine intranasal
naphazoline decreases levels of nicotine intranasal by Other (see comment). Use Caution/Monitor. Comment: Nasal vasoconstrictors prolong the time to peak concentrations by ~40% and decreases peak concentration by ~20%.
- safinamide
naphazoline and safinamide both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Monitor patients for hypertension if safinamide is prescribed concomitantly with prescription or nonprescription sympathomimetics, including nasal, oral, or ophthalmic decongestants and cold remedies.
- solriamfetol
naphazoline and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
Minor (0)
Adverse Effects
Frequency Not Defined
CNS (anxiety, dizziness, tremor, etc)
Burning
Stinging
Sneezing
Dryness
Local irritation
Rebound congestion
Warnings
Contraindications
Heart disease (incr BP, HR, palpitations)
Narrow angle glaucoma
Cautions
Caution in HTN, hyperthyroidism, ocular injury, DM, open-angle glaucoma
Overuse may cause rebound congestion
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Alpha 1 adrenergic agonist; stimulates alpha-adrenergic receptors in nasal conjunctiva and arterioles to produce vasoconstriction that results in nasal decongestion
Pharmacokinetics
Absorption: minimal systemic
Onset: 10 min
Duration: 2-6 hr
